ImmuneOncia Rights Offering Finalized at 4,860 Won, Operating Funds Adjusted to 81.8B Won
Correction filing: Subsidiary ImmuneOncia corrects rights offering decision. Final issuance price set at 4,860 won (22.4% decline from expected 6,260 won). Operating fund target reduced by 22.4% from 105.36B won to 81.79B won.
Offering size: 16,830,200 common shares (pre-offering: 74,363,829 shares), allocation ratio of 0.2263223966 shares per existing share. Payment date: May 21, 2026.
Schedule: Record date April 6, 2026; subscription period for existing shareholders May 13-14, 2026. Lead manager: Korea Investment & Securities.
Other: ImmuneOncia is a subsidiary of Yuhan Corporation (total assets 26.19B won, 0.89% of parent's consolidated assets), not a major subsidiary.
KOSPI Filing Information
Filing: [Correction of Description] Decision on Paid-in Capital Increase (Major Management Matters of Subsidiary)